Caribou Biosciences, Inc. (CRBU)

NASDAQ: CRBU · IEX Real-Time Price · USD
2.290
-0.110 (-4.58%)
At close: Jul 19, 2024, 4:00 PM
2.380
+0.090 (3.93%)
After-hours: Jul 19, 2024, 7:37 PM EDT
-4.58%
Market Cap 207.28M
Revenue (ttm) 33.40M
Net Income (ttm) -115.26M
Shares Out 90.32M
EPS (ttm) -1.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,162,416
Open 2.370
Previous Close 2.400
Day's Range 2.240 - 2.410
52-Week Range 1.500 - 8.330
Beta 2.28
Analysts Strong Buy
Price Target 15.67 (+584.28%)
Earnings Date Aug 6, 2024

About CRBU

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or r... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 23, 2021
Employees 158
Stock Exchange NASDAQ
Ticker Symbol CRBU
Full Company Profile

Financial Performance

In 2023, CRBU's revenue was $34.48 million, an increase of 148.91% compared to the previous year's $13.85 million. Losses were -$102.07 million, 2.66% more than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price forecast is $15.67, which is an increase of 584.28% from the latest price.

Price Target
$15.67
(584.28% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU

NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU). Such investors are ad...

6 days ago - Accesswire

Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: C...

11 days ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU

NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. (“Caribou” or the “Company”) (NASDAQ: CRBU). Such investors are ad...

13 days ago - GlobeNewsWire

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER...

6 weeks ago - GlobeNewsWire

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's par...

7 weeks ago - GlobeNewsWire

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts h...

3 months ago - GlobeNewsWire

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract on ...

3 months ago - GlobeNewsWire

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safet...

3 months ago - GlobeNewsWire

HireRight Holdings Corp. (HRT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK--(BUSINESS WIRE)---- $CRBU #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HireRight Holdings Corp. (“HireR...

Other symbols: HRT
4 months ago - Business Wire

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

-- 30 th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- -- 1 st patient dosed in CB-012 AMpLify Phase 1 trial for patie...

4 months ago - GlobeNewsWire

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc.  (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's p...

5 months ago - GlobeNewsWire

Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

-- Tim Kelly to lead Caribou's technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate piv...

6 months ago - GlobeNewsWire

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial continues...

7 months ago - GlobeNewsWire

Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

-- CB-010 ANTLER Phase 1 trial continues enrolling second-line r/r LBCL patients in dose expansion; plan to share FDA feedback by year-end 2023 and report initial dose expansion data in H1 2024 -- -- ...

9 months ago - GlobeNewsWire

Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

-- Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma -- BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) --  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clin...

9 months ago - GlobeNewsWire

Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

-- AMpLify Phase 1 clinical trial to initiate patient enrollment by mid-2024 -- -- CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption and immune cloaking to enter the cl...

9 months ago - GlobeNewsWire

Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer

BERKELEY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment...

10 months ago - GlobeNewsWire

Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1 tria...

1 year ago - GlobeNewsWire

Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of a...

1 year ago - GlobeNewsWire

Caribou Biosciences offers more stock, and shares fall

Shares of Caribou Biosciences Inc. CRBU, +4.90% tumbled 9.7% after hours on Thursday after the biopharma company said it had begun a $100 million share offering. The company, which focuses on genome e...

1 year ago - Market Watch

Caribou's cell therapy shows promise in early-stage cancer study

Caribou Biosciences Inc said on Thursday its experimental CAR T-cell therapy helped clear all signs or decrease tumor size in 94% of patients being treated for a type of cancer in the lymph nodes in a...

1 year ago - Reuters

Caribou Biosciences Announces Proposed Public Offering of Common Stock

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has commenced...

1 year ago - GlobeNewsWire

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR) rate,...

1 year ago - GlobeNewsWire

Pfizer makes equity investment in Caribou Biosciences

Pfizer has invested $25 million to buy a minority stake in Caribou Biosciences , making it the latest small biotechnology firm to attract the pharmaceutical giant's interest.

Other symbols: PFE
1 year ago - Reuters

Caribou Biosciences stock soars after Pfizer buys stock priced at a 31% premium

Shares of Caribou Biosciences Inc. CRBU ran up 21.3% toward a three-month high in premarket trading Thursday, after the genome-editing biopharmaceutical company said drug giant Pfizer Inc. has made a ...

Other symbols: PFE
1 year ago - Market Watch